Meng W, Zhu HH, Xu ZF, Cai SR, Dong Q, Pan QR, Zheng S, Zhang SZ. Serum M2-pyruvate kinase: A promising non-invasive biomarker for colorectal cancer mass screening. World J Gastrointest Oncol 2012; 4(6): 145-151 [PMID: 22737276 DOI: 10.4251/wjgo.v4.i6.145]
Corresponding Author of This Article
Dr. Su-Zhan Zhang, MD, PhD, Professor, Zhejiang University Cancer Institute, 88 Jiefang Road, Hangzhou 310009, Zhejiang Province, China. zuci@zju.edu.cn
Article-Type of This Article
Brief Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Jun 15, 2012; 4(6): 145-151 Published online Jun 15, 2012. doi: 10.4251/wjgo.v4.i6.145
Table 1 Basic characteristics of study population for the value of serum pyruvate kinase Isoenzyme M2 and carcinoembryonic antigen in colorectal cancer mass screening in Hangzhou, China, 2006-2008 (mean ± SD)
Colorectal lesion
n
Gender
Age (yr)
M2-PK (U/mL)
CEA (ng/mL)
Male
Female
Colorectal cancer
Stage I and II
55
53
40
59.17 ± 10.71
13.10 ± 12.07
5.74 ± 7.49
Stage III
38
14.75 ± 13.39
5.68 ± 5.43
Advanced adenoma
41
25
16
60.17 ± 7.78
8.58 ± 7.65
2.68 ± 1.43
Adenoma
137
68
69
60.34 ± 8.16
6.70 ± 6.97
2.58 ± 3.74
Nonadenomatous polyp
47
25
22
59.04 ± 8.08
5.13 ± 3.73
2.55 ± 2.09
IBD
7
1
6
57.43 ± 7.16
2.51 ± 1.94
1.71 ± 0.91
Normal
158
56
102
57.15 ± 7.96
2.96 ± 2.17
1.98 ± 1.02
Table 2 The area under the receiver operating characteristic curve and 95% confidence interval of serum pyruvate kinase isoenzyme M2 in U/mL and carcinoembryonic antigen in ng/mL in diagnosing colorectal lesions in colorectal cancer mass screening in Hangzhou, China, 2006-2008
Colorectal lesion
Test
AUC
SE
P-value
95% CI
CRC stage I and II
CEA
0.70
0.04
< 0.0001
0.62-0.79
M2-PK
0.89
0.03
< 0.0001
0.84-0.94
CRC stage III
CEA
0.73
0.05
< 0.0001
0.63-0.83
M2-PK
0.89
0.03
< 0.0001
0.84-0.94
Advanced adenoma
CEA
0.63
0.05
0.01
0.53-0.73
M2-PK
0.81
0.04
< 0.0001
0.74-0.86
Adenoma
CEA
0.54
0.03
0.28
0.47-0.60
M2-PK
0.69
0.03
< 0.0001
0.64-0.76
Nonadenomatous polyp
CEA
0.58
0.05
0.09
0.48-0.68
M2-PK
0.69
0.04
< 0.0001
0.62-0.78
Inflammatory bowel disease
CEA
0.41
0.10
0.40
0.21-0.61
M2-PK
0.42
0.10
0.40
0.21-0.63
Table 3 Diagnostic sensitivity and specificity in percentage at 95% confidence interval of serum M2-pyruvate kinase using various cut-off value settings for different colorectal lesions compared with 158 normal people in colorectal cancer mass screening in Hangzhou, 2006-2008 (95% CI)
M2-PK (U/mL)
Colorectal cancer
Advanced adenoma
Adenoma
Non-adenomatous polyp
Sensitivity
Specificity
Sensitivity
Specificity
Sensitivity
Specificity
Sensitivity
Specificity
2.00
100.00 (100.00-100.00)
40.51 (32.85-48.16)
95.12 (88.53-100.00)
40.51 (32.85-48.16)
82.48 (76.12-88.85)
40.51 (32.85-48.16)
82.98 (72.23-93.72)
40.51 (32.85-48.16)
2.50
94.62 (90.04-99.21)
55.06 (47.31-62.82)
85.37 (74.55-96.18)
55.06 (47.31-62.82)
71.53 (63.98-79.09)
55.06 (47.31-62.82)
76.60 (64.49-88.70)
55.06 (47.31-62.82)
3.00
91.40 (85.70-97.10)
65.19 (57.76-72.62)
75.61 (62.46-88.75)
65.19 (57.76-72.62)
61.31 (53.16-69.47)
65.19 (57.76-72.62)
65.96 (52.41-79.50)
65.18 (57.76-72.62)
3.50
87.10 (80.28-93.91)
68.99 (61.78-76.20)
73.17 (59.61-86.73)
68.99 (61.78-76.20)
56.93 (48.64-65.23)
68.99 (61.78-76.20)
55.32 (41.11-69.53)
68.99 (61.78-76.20)
4.00
81.72 (73.87-89.58)
74.05 (67.22-80.89)
65.85 (51.34-80.37)
74.05 (67.22-80.89)
49.64 (41.26-58.01)
74.05 (67.22-80.89)
48.94 (34.64-63.23)
74.05 (67.22-80.89)
Table 4 Positive predictive value and negative predictive value in percentage at 95% confidence interval of serum M2-pyruvate kinase using various cut-off value settings for different colorectal lesions compared with 158 normal people in colorectal cancer mass screening in Hangzhou, China, 2006-2008 (95% CI)
M2-PK (U/mL)
Colorectal cancer
Advanced adenoma
Adenoma
Nonadenomatous polyps
PPV
NPV
PPV
NPV
PPV
NPV
PPV
NPV
2.00
49.73 (42.57-56.90)
100.00 (100.00-100.00)
29.32 (21.59-37.06)
96.97 (92.83-100.00)
54.59 (47.81-61.37)
72.73 (63.42-82.03)
29.32 (21.59-37.06)
88.89 (81.63-96.15)
2.50
55.35 (47.62-63.07)
94.57 (89.93-99.20)
33.02 (24.07-41.97)
93.55 (88.56-98.54)
57.99 (50.55-65.43)
69.05 (60.98-77.12)
33.64 (24.69-42.60)
88.78 (82.23-95.03)
3.00
60.71 (52.62-68.80)
92.79 (87.98-97.60)
36.05 (25.90-46.19)
91.15 (85.91-96.39)
60.43 (52.30-68.56)
66.03 (58.59-73.46)
36.05 (25.90-46.19)
86.55 (80.43-92.68)
3.50
62.31 (53.98-70.64)
90.08 (84.76-95.41)
37.97 (27.27-48.68)
90.83 (85.67-96.00)
61.42 (52.95-69.88)
64.88 (57.66-72.10)
34.67 (23.90-45.44)
83.85 (77.52-90.17)
4.00
64.96 (56.31-73.60)
87.31 (67.22-80.89)
39.71 (28.08-51.34)
89.31 (84.02-94.60)
62.39 (53.29-71.48)
62.90 (55.96-69.85)
35.94 (24.18-47.69)
82.98 (76.78-89.18)
Citation: Meng W, Zhu HH, Xu ZF, Cai SR, Dong Q, Pan QR, Zheng S, Zhang SZ. Serum M2-pyruvate kinase: A promising non-invasive biomarker for colorectal cancer mass screening. World J Gastrointest Oncol 2012; 4(6): 145-151